Curaleaf Holdings, Inc. reported unaudited Q1 2026 results showing a sharp move to profitability driven largely by income tax effects. Net revenues reached $324.2M, up from $306.6M a year earlier, with gross profit of $157.3M.
The company generated net income of $69.8M versus a net loss of $(61.1)M in Q1 2025, and basic and diluted EPS of $0.09 compared with a loss of $(0.10) per share. Results were heavily influenced by a benefit for income taxes of $98.7M, tied to changes in uncertain tax positions including Curaleaf’s treatment of Section 280E.
Operating cash flow from continuing operations was $21.3M, while cash and cash equivalents were $106.1M as of March 31, 2026. Total assets were $2.81B and total liabilities $1.90B, with shareholders’ equity increasing to $821.1M.
Curaleaf Holdings, Inc. has scheduled its virtual Annual and Special Meeting of shareholders for June 22, 2026 at 9:00 a.m. Eastern time. Shareholders of record at the close of business on May 5, 2026 will be entitled to receive notice and vote.
Items to be voted on include director elections, auditor appointment and authorization of their remuneration, renewal of the Company’s 2018 Stock and Incentive Plan including unallocated awards, and a special resolution to amend the Company’s multiple voting shares to eliminate the MVS sunset within one year after a U.S. stock exchange listing, while keeping other existing sunsets.
Shareholders will also consider an ordinary resolution approving an exchange of certain stock options (with exercise prices or performance vesting tied to a trading price per share of at least US$5.00) for new restricted share units under the LTIP, including insider participation, and a special resolution approving a plan of arrangement to continue the Company from British Columbia to Delaware. Meeting materials will be delivered using notice-and-access and made available on SEDAR+ and EDGAR.
Curaleaf Holdings, Inc. filed a Form 6-K to announce the appointment of Torsten Greif to its Board of Directors. Greif is a founder of Four 20 Pharma GmbH, Curaleaf’s flagship German brand in the medical cannabis market.
The company highlights his experience in cannabis cultivation, regulatory strategy, and brand development, noting that under his leadership Four 20 Pharma completed a majority stake sale to Curaleaf. His board role is positioned as supporting Curaleaf’s European expansion and delivery of EU-GMP-certified medical cannabis across Germany and other regulated markets.
Curaleaf Holdings has completed the buyout of the remaining 45% stake it did not already own in Four 20 Pharma GmbH, making the German medical cannabis producer a wholly owned subsidiary. Four 20 Pharma is fully EU-GMP and GDP licensed and supplies nursing homes, pharmacies, and research institutions across Germany and select European markets.
The acquisition strengthens Curaleaf’s vertically integrated global supply chain, linking cultivation in Portugal and Canada with licensed distribution in Germany to support a seed-to-patient quality model. Curaleaf has also launched the Four 20 brand in the United Kingdom and Poland and plans further international expansion based on Four 20 Pharma’s quality and compliance blueprint.
Curaleaf Holdings has launched a share repurchase program approved by its board and the Toronto Stock Exchange. The normal course issuer bid allows the company to buy back up to 34,388,831 Subordinate Voting Shares, representing about 5% of the 687,776,631 shares issued and outstanding as of April 10, 2026, with an estimated aggregate value of about U.S.$83 million based on the April 14, 2026 TSX closing price.
The program runs from April 20, 2026 to no later than April 19, 2027. Purchases will be made through the TSX and eligible alternative trading systems, generally capped at 210,139 shares per day, equal to 25% of the 840,559-share average daily trading volume. Any repurchased shares will be cancelled, and the company notes it has not used a similar bid in the past 12 months.
Curaleaf Holdings has extended an existing automatic securities disposition plan (ASDP) for its Chief Legal Officer, Peter Clateman, effective March 31, 2026. The plan covers the orderly exercise of vested stock options that are scheduled to expire in July 2027 and the sale of a portion of the resulting Subordinate Voting Shares to pay anticipated taxes.
Share sales under the ASDP are expected to begin on or about July 1, 2026 and continue for roughly six months, with transactions executed by an independent broker at prevailing market prices within preset trading, price and volume parameters. The ASDP was approved by the company’s compensation committee, includes restrictions on amendments or termination, and all dispositions will be reported under applicable U.S. and Canadian securities laws with disclosure that they arise from the ASDP.
Curaleaf Holdings, Inc. filed a Form 6-K as a foreign private issuer to share a press release about its upcoming first quarter 2026 results. The company plans to report financial and operational results for the quarter ended March 31, 2026 after market close on May 5, 2026.
Management will host a conference call and webcast on May 5, 2026 at 5:00 p.m. ET, including prepared remarks and a question-and-answer session. The filing also provides dial-in details, replay information available until May 12, 2026, and links to Curaleaf’s investor relations resources.
Curaleaf Holdings, Inc. is issuing US$500,000,000 of 11.50% Senior Secured Notes due February 18, 2029 under a Fourth Supplemental Indenture. The notes pay 11.50% interest semi-annually in U.S. dollars, starting August 18, 2026, and may be issued in additional tranches on the same terms.
Before August 18, 2027, Curaleaf can redeem up to 35% of the notes at par plus 100% of the coupon and accrued interest using net cash from qualifying equity offerings. From August 18, 2027, the notes are redeemable at 105.750% of principal, and at 100.000% from February 18, 2028 onward, plus accrued interest.
Curaleaf Holdings, Inc. filed its Annual Report on Form 40-F for the fiscal year ended December 31, 2025, reporting 678,504,043 Subordinate Voting Shares outstanding as of that date. Management concluded that the Company’s disclosure controls and internal control over financial reporting were effective as of December 31, 2025, and the report incorporates audited consolidated financial statements and MD&A as exhibits.
The filing names PKF O'Connor Davies, LLP and related PKF firms as independent auditors, lists aggregate auditor fees for 2025 and 2024, and includes an exhibit index with the Annual Information Form, audited financials, officer certifications and an earnings release dated February 26, 2026.
Curaleaf Holdings has closed a private placement of US$500 million aggregate principal amount of 11.5% senior secured notes due February 18, 2029. The notes were issued at 100% of face value and are payable semi-annually until maturity, unless earlier redeemed or purchased.
The company redeemed its previously outstanding US$475 million senior secured notes due December 15, 2026, extending its debt maturity profile while raising additional capital. Curaleaf plans to use net proceeds to support global growth initiatives and to pay transaction fees and expenses, under an indenture that also permits additional note issuance and up to US$100 million of senior bank financing.